The DOI matches its Crossref record.
Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children’s Cancer Group Study
Abstract
PURPOSE: A prospective Children’s Cancer Group study, CCG-3881, has been completed to determine if a more accurate prediction of prognosis by biologic features can identify subgroups of infants with stage IV neuroblastoma (NBL) who require differing intensities of treatment. PATIENTS AND METHODS: One hundred thirty-four infants were registered from June 1989 to August 1995, with a median follow-up of 47.1 months (range, 0 to 88 months). The biologic factors examined were tumor MYCN copy number, Shimada histopathologic classification, serum ferritin, and bone marrow immunocytology (sensitivity, one tumor cell per 10 5 bone marrow cells). Patients treated on CCG-3881 (n = 116) received four-drug chemotherapy for 9 months (cisplatin, cyclophosphamide, doxorubicin, and etoposide), with surgery and local radiation to residual disease. After January 1991, all subsequent infants with tumor MYCN amplification (n = 18) were transferred after one cycle of therapy to the high-risk CCG-3891 protocol (open January 1991 to April 1996) for more intensive treatment. RESULTS: The 3-year event-free survival (EFS) and overall survival (mean ± SD) for the 134 infants were 63% ± 5% and 71% ± 5%, respectively. Patients whose tumors were without MYCN amplification had a 93% ± 4% 3-year EFS, whereas those with amplified MYCN had a 10% ± 7% 3-year EFS (P < .0001). Each of the other biologic features studied had prognostic significance in univariate analysis but not after stratifying by MYCN copy number. CONCLUSION: Infants less than 1 year of age at diagnosis with stage IV NBL have a much improved outcome compared with children ≥ 1 year of age. Nonamplified MYCN tumors identify a group of infants with a 93% ± 4% EFS, whereas amplified MYCN copy number clearly identifies patients who are unlikely to survive despite intensive chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Neuroblastoma: biological insights into a clinical enigma
Brodeur, G. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1014 · Cited by 2,160
Self-citationNeuroblastoma: Biology, Prognosis, and Treatment
Park, J. R., Eggert, A., & Caron, H. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.011 · Cited by 620
London, W. B., Castleberry, R. P., Matthay, K. K., Look, A. T., Seeger, R. C., Shimada, H., Thorner, P., Brodeur, G., Maris, J. M., Reynolds, C. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.571 · Cited by 589
Self-citationRevised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
Irwin, M. S., Naranjo, A., Zhang, F. F., Cohn, S. L., London, W. B., Gastier-Foster, J. M., Ramirez, N. C., Pfau, R., Reshmi, S., Wagner, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00278 · Cited by 494
Self-citationIrwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Metadata
- Authors
- Schmidt, M. L., Lukens, J. N., Seeger, R. C., Brodeur, G. M., Shimada, H., Gerbing, R. B., Stram, D. O., Perez, C., Haase, G. M., & Matthay, K. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-03-13
- Volume
- 18
- Issue
- 6
- Pages
- 1260-1268
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1959376412
- Cited by
- 241
- References
- 0
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children’s Cancer Group Study. https://app.cochat.ai/papers/10.1200/jco.2000.18.6.1260
- The paper
- Schmidt, M. L., Lukens, J. N., Seeger, R. C., Brodeur, G. M., Shimada, H., Gerbing, R. B., Stram, D. O., Perez, C., Haase, G. M., & Matthay, K. K. (2000). Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children’s Cancer Group Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.6.1260
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.